BRPI1012196A2 - composição compreendendo gotas de óleo - Google Patents

composição compreendendo gotas de óleo

Info

Publication number
BRPI1012196A2
BRPI1012196A2 BRPI1012196A BRPI1012196A BRPI1012196A2 BR PI1012196 A2 BRPI1012196 A2 BR PI1012196A2 BR PI1012196 A BRPI1012196 A BR PI1012196A BR PI1012196 A BRPI1012196 A BR PI1012196A BR PI1012196 A2 BRPI1012196 A2 BR PI1012196A2
Authority
BR
Brazil
Prior art keywords
composition
oil droplets
droplets
oil
Prior art date
Application number
BRPI1012196A
Other languages
English (en)
Inventor
Francis Mcdonald Bernard
Coulter Ivan
Aversa Vincenzo
Original Assignee
Sigmoid Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43126572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012196(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigmoid Pharma Ltd filed Critical Sigmoid Pharma Ltd
Publication of BRPI1012196A2 publication Critical patent/BRPI1012196A2/pt
Publication of BRPI1012196B1 publication Critical patent/BRPI1012196B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
BRPI1012196-0A 2009-05-18 2010-05-18 Composição compreendendo gotas de óleo BRPI1012196B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17912109P 2009-05-18 2009-05-18
US61/179,121 2009-05-18
IE2009/0381 2009-05-18
IE20090381 2009-05-18
PCT/EP2010/056838 WO2010133609A2 (en) 2009-05-18 2010-05-18 Composition comprising oil drops

Publications (2)

Publication Number Publication Date
BRPI1012196A2 true BRPI1012196A2 (pt) 2018-02-27
BRPI1012196B1 BRPI1012196B1 (pt) 2021-11-30

Family

ID=43126572

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012196-0A BRPI1012196B1 (pt) 2009-05-18 2010-05-18 Composição compreendendo gotas de óleo

Country Status (14)

Country Link
US (5) US9278070B2 (pt)
EP (3) EP3300723A1 (pt)
JP (1) JP5640079B2 (pt)
CN (2) CN105213318A (pt)
BR (1) BRPI1012196B1 (pt)
CA (1) CA2762179A1 (pt)
DK (2) DK2432455T3 (pt)
ES (2) ES2649112T3 (pt)
GB (1) GB2483815B (pt)
HR (1) HRP20150110T1 (pt)
PL (1) PL2471518T3 (pt)
SG (1) SG176145A1 (pt)
SI (1) SI2432455T1 (pt)
WO (1) WO2010133609A2 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3300723A1 (en) * 2009-05-18 2018-04-04 Sigmoid Pharma Limited Composition comprising oil drops
JP5911799B2 (ja) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012094346A2 (en) 2011-01-03 2012-07-12 The Regents Of The University Of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
CA2865917C (en) * 2011-03-01 2020-09-29 4413261 Canada Inc. (Spencer Canada) Two speed monolithic system for controlled release of drugs
ITMI20111050A1 (it) 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
US9724304B2 (en) 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN103054796B (zh) * 2012-12-11 2014-07-16 山东省眼科研究所 一种环孢素a胶束滴眼液及其制备方法
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN105828809B (zh) * 2013-12-20 2019-10-29 费森尤斯卡比德国有限公司 包含脂质和活性药剂的具有聚合物涂层的微胶囊
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
CA2940599A1 (en) * 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
AU2015246030B2 (en) * 2014-04-09 2020-03-12 Pulse Pharmaceuticals Pvt Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
EP2932956B1 (de) * 2014-04-14 2017-12-27 Symrise AG Kapseln mit hoher Wirkstoffbeladung
WO2015176780A1 (en) 2014-05-23 2015-11-26 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
US20150342893A1 (en) * 2014-05-29 2015-12-03 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
CA2954590C (en) 2014-07-21 2023-09-19 Sevecom S.P.A. Powdered emulsion for animal feed
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
EP3180397A1 (en) * 2014-08-15 2017-06-21 Dow Global Technologies LLC Ethylcellulose dispersion and powder
EP3215127B1 (en) * 2014-11-07 2020-10-28 Sublimity Therapeutics Limited Compositions comprising cyclosporin
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
WO2016193588A1 (fr) * 2015-05-29 2016-12-08 Galderma Research & Development Compositions comprenant au moins un principe actif disperse et des microcapsules lipidiques
US10227527B2 (en) 2015-12-14 2019-03-12 Indizen Optical Technologies of America, LLC Nanoemulsion optical materials
WO2017131003A1 (ja) 2016-01-25 2017-08-03 サントリーホールディングス株式会社 機能性物質を含有するカプセル及びその製造方法
JP6103111B1 (ja) 2016-05-24 2017-03-29 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
WO2018209293A2 (en) * 2017-05-11 2018-11-15 The Regents Of The University Of California Nanoscale multiple emulsions and nanoparticles
US11464744B2 (en) * 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
DE20168827T1 (de) 2017-06-30 2021-01-21 Gtx Medical B.V. System zur neuromodulierung
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019110400A1 (en) 2017-12-05 2019-06-13 Ecole Polytechnique Federale De Lausanne (Epfl) A system for planning and/or providing neuromodulation
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
AR115269A1 (es) * 2018-03-15 2020-12-16 Scherer Technologies Llc R P Cápsulas de gelatina blanda entéricas
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US10828286B2 (en) * 2018-05-24 2020-11-10 Gm Pharmaceuticals, Inc. Niacin and berberine compositions and methods of use thereof
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
KR102193575B1 (ko) * 2018-12-21 2021-01-04 주식회사 메가코스 오일-드롭 메이크업 화장료 조성물
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
JP6767605B1 (ja) * 2019-03-29 2020-10-14 積水化学工業株式会社 コアシェル構造体、製剤、外用薬、テープ剤及び化粧品
US11525081B2 (en) * 2019-04-29 2022-12-13 King Fahd University Of Petroleum And Minerals Methods of inhibiting corrosion in acid stimulation operations
WO2020251039A1 (ja) * 2019-06-14 2020-12-17 森下仁丹株式会社 遅延崩壊型カプセルおよびその製造方法
CN114650833A (zh) 2019-09-13 2022-06-21 芬奇治疗控股有限责任公司 用于治疗孤独症谱群障碍的组合物和方法
CN115038430A (zh) * 2019-10-18 2022-09-09 快饮科学公司 自微乳化的多种可递送物的系统
US20240131082A1 (en) 2019-10-18 2024-04-25 Finch Therapeutics Holdings Llc Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
EP3827871A1 (en) 2019-11-27 2021-06-02 ONWARD Medical B.V. Neuromodulation system
IL271766B (en) 2019-12-30 2021-04-29 Fischer Pharma Ltd Molded material for topical administration and its uses
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
EP4125913A4 (en) * 2020-03-30 2023-08-23 IGIA Pharmaceuticals, Inc. PEDIATRIC TYROSINE KINASE INHIBITOR FORMULATION
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
CN116348094A (zh) 2020-07-28 2023-06-27 诺施达制药股份有限公司 新的胃滞留延长释放剂型
WO2022178294A1 (en) 2021-02-19 2022-08-25 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
CN114532339A (zh) * 2021-12-23 2022-05-27 武汉轻工大学 一种用于水产养殖的皂化包裹抗菌药物的制备方法

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3971852A (en) 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4045589A (en) 1976-06-21 1977-08-30 Carnation Company Fat emulsion product and process for producing the same
IT1090703B (it) 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
US4123403A (en) 1977-06-27 1978-10-31 The Dow Chemical Company Continuous process for preparing aqueous polymer microsuspensions
DE2907460A1 (de) 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4279632A (en) 1979-05-08 1981-07-21 Nasa Method and apparatus for producing concentric hollow spheres
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
JPS6415Y2 (pt) 1981-05-29 1989-01-05
DE3224619A1 (de) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JPS5877810A (ja) 1981-11-01 1983-05-11 Taiho Yakuhin Kogyo Kk ポリグリセロ−ル不飽和脂肪酸エステルを含む経口薬剤組成物
JPS5813508A (ja) 1981-07-14 1983-01-26 Taiho Yakuhin Kogyo Kk ポリグリセロール飽和脂肪酸エステルを含む経口薬剤組成物
US4481157A (en) 1982-04-27 1984-11-06 Morishita Jintan Co., Ltd. Method and apparatus for production of microcapsules
US4597959A (en) 1982-04-30 1986-07-01 Arthur Barr Sustained release breath freshener, mouth and palate coolant wafer composition and method of use
US4422985A (en) 1982-09-24 1983-12-27 Morishita Jintan Co., Ltd. Method and apparatus for encapsulation of a liquid or meltable solid material
JPS5988420A (ja) 1982-11-12 1984-05-22 Teisan Seiyaku Kk シ−ムレスカプセル化ニフエジピン製剤
JPS5988420U (ja) 1982-12-04 1984-06-15 有限会社三和ボタン店 学生服の詰襟構造
US4502888A (en) 1982-12-13 1985-03-05 The Dow Chemical Company Aqueous dispersions of plasticized polymer particles
JPS59131355A (ja) 1983-01-17 1984-07-28 森下仁丹株式会社 多重軟カプセルの製法
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
DE3331009A1 (de) 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4615892A (en) 1983-09-12 1986-10-07 Grain Processing Corporation Dried emulsion concentrates hydratable to edible spreads
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4659700A (en) 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
JPS6115119A (ja) 1984-07-02 1986-01-23 Yokogawa Hokushin Electric Corp レ−ザプリンタ
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61115462A (ja) 1984-11-13 1986-06-03 Denka Seiyaku Kk 甘味増強ステビア葉の製法
JPS61126016A (ja) * 1984-11-22 1986-06-13 Toagosei Chem Ind Co Ltd 不飽和脂肪酸を内相物としたマイクロカプセル
US4601894A (en) 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
EP0241806A1 (en) 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4857335A (en) 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
WO1989001772A1 (en) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4910191A (en) 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2806564B2 (ja) 1989-07-20 1998-09-30 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5260071A (en) 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU654824B2 (en) * 1990-06-29 1994-11-24 Chiron Corporation Vaccine compositions containing liposomes
JP3179132B2 (ja) 1990-07-04 2001-06-25 塩野義製薬株式会社 非粘着性皮膜形成法
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5418010A (en) 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
ATE161707T1 (de) 1991-06-28 1998-01-15 Univ Brown Res Found Kapselextrusionssysteme
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
JPH0549899A (ja) 1991-08-09 1993-03-02 Japan Tobacco Inc ビーズ及びこれを製造するための液滴生成装置
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU666895B2 (en) 1991-12-30 1996-02-29 Hercules Incorporated High load spray dry encapsulation
DE4201179A1 (de) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
AU3343093A (en) 1992-01-17 1993-08-03 Alfatec-Pharma Gmbh Pellets containing peptide drugs, their manufacture and use
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
DE69324523T2 (de) 1992-06-12 1999-09-09 Kao Corp Badezusatzzusammensetzung enthaltend oberflächenaktive Mittel enthaltende nahtlose Kapsel und Verfahren zur Herrstellung der Kapsel
JP3405746B2 (ja) 1992-10-28 2003-05-12 フロイント産業株式会社 シームレスカプセルの製造方法
DE69332031T2 (de) 1993-01-08 2002-12-19 Csl Ltd Impfstoffpräparate
GB9300875D0 (en) 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH06254382A (ja) * 1993-03-05 1994-09-13 Riken Vitamin Co Ltd マイクロカプセルの製造法およびその製造装置
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
CN1077800C (zh) 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
FR2707184B1 (fr) 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
DE4332041C2 (de) 1993-09-21 1997-12-11 Rentschler Arzneimittel Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995022343A1 (fr) 1994-02-17 1995-08-24 Shiseido Company, Ltd. Composition d'emulsion a base de cyclosporine
US5498439A (en) 1994-03-04 1996-03-12 Arnhem, Inc. Process for encapsulating the flavor with colloid gel matrix
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5650232A (en) 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5827531A (en) 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5529783A (en) 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5674495A (en) 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5595757A (en) 1995-03-29 1997-01-21 Warner-Lambert Company Seamless capsules
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
RO119815B1 (ro) 1995-08-25 2005-04-29 Sangstat Medical Corporation Compoziţie orală cu ciclosporină
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
JP3759986B2 (ja) 1995-12-07 2006-03-29 フロイント産業株式会社 シームレスカプセルおよびその製造方法
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
KR0183449B1 (ko) 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제
WO1998018610A1 (en) 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
JP2001515491A (ja) 1997-03-12 2001-09-18 アボツト・ラボラトリーズ 親油性化合物の投与のための親油性二成分系
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
AU7201998A (en) 1997-05-06 1998-11-27 Zhi Liu Drug delivery system
JP4102459B2 (ja) 1997-05-14 2008-06-18 森下仁丹株式会社 生体高分子を合成するシームレスカプセルおよびその製造方法
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
CA2294031E (en) 1997-07-29 2012-04-03 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3090198B2 (ja) 1997-08-21 2000-09-18 日本電気株式会社 半導体装置の構造およびその製造方法
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO1999022719A1 (fr) 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
IT1296585B1 (it) 1997-11-28 1999-07-14 Uni Di Pavia Microcapsule contenenti materiale seminale per l'inseminazione strumentale nella specie suina
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US6174466B1 (en) 1998-05-08 2001-01-16 Warner-Lambert Company Methods for making seamless capsules
JPH11322587A (ja) 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
US20040166183A1 (en) * 1998-05-20 2004-08-26 Ruseler-Van Embden Johanna G. H. Methods and means for preventing or treating inflammation or pruritis
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
KR100602725B1 (ko) 1998-12-11 2006-07-20 파마솔루션스, 인코포레이티드 물에서 불충분하게 용해되는 약제를 위한 자가-유화용조성물
JP3039863B1 (ja) 1998-12-25 2000-05-08 不二精工株式会社 ロッキングプレス装置
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2000302654A (ja) 1999-04-16 2000-10-31 Kao Corp 歯磨組成物の製造法
US8663692B1 (en) 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
WO2000069420A1 (en) 1999-05-14 2000-11-23 Coraltis Ltd. Pulse-delivery oral compositions
EP1184038B1 (en) 1999-06-09 2005-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
BR0012869A (pt) 1999-07-30 2002-05-21 Smithkline Beecham Plc Forma de dosagem farmacêutica de componentes múltiplos
EP1227793A1 (en) 1999-11-02 2002-08-07 Cipla Ltd. Cyclosporin formulation
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004504264A (ja) 2000-01-07 2004-02-12 ユニバーシティ　オブ　シンシナティ Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化
EP1287039A1 (en) 2000-04-28 2003-03-05 University College Dublin Amphiphilic macrocyclic derivatives and their analogues
US6656470B2 (en) 2000-05-12 2003-12-02 Pharmacia & Upjohn Company Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
US20040258702A1 (en) 2000-06-22 2004-12-23 Blonder Joan P. Vaccine delivery
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
ES2310201T3 (es) 2001-02-13 2009-01-01 Government Of The United States Of America, As Represented By The Secretary Of The Army Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
CN1203843C (zh) * 2001-04-10 2005-06-01 中国科学院成都有机化学研究所 一种高含量油溶性维生素缓释微囊粉的制备方法
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
FR2830447B1 (fr) 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US20050129718A1 (en) 2001-12-20 2005-06-16 Sherman Bernard C. Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
AU2002348747A1 (en) 2002-01-10 2003-07-24 Firmenich Sa Process for the preparation of extruded delivery systems
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
US6974592B2 (en) 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
JP4226846B2 (ja) 2002-06-07 2009-02-18 キャタレント・ジャパン株式会社 口腔内で崩壊可能なソフトカプセル剤
JP2004043332A (ja) 2002-07-09 2004-02-12 Nof Corp 経口用リポソーム製剤
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
CA2499423A1 (en) 2002-09-04 2004-03-18 Niraj Vasisht Microencapsulation of oxygen or water sensitive materials
WO2004042024A2 (en) 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004064997A1 (en) 2003-01-23 2004-08-05 Inotech Ag New microcapsules useful as extraction means in particular for extracting water or soil contaminants
EP1608347B1 (en) 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
ES2398235T3 (es) 2003-04-04 2013-03-14 Pah Usa 15 Llc Emulsiones de aceite en agua microfluidizadas y composiciones de vacunas
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1663216B1 (en) 2003-08-29 2011-11-02 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050095288A1 (en) 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
NZ546974A (en) 2003-11-21 2008-06-30 Commw Scient Ind Res Org Gastrointestinal tract delivery systems
EP1697511A4 (en) 2003-12-11 2007-11-21 Vaxdesign Corp IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME
CN1268325C (zh) 2004-01-18 2006-08-09 浙江大学 三重复合微球制剂及其制备方法
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
PE20060003A1 (es) 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
FR2867395B1 (fr) 2004-03-15 2006-06-16 Rhodia Chimie Sa Emulsion sechee, son procede de preparation, et ses utilisations
BRPI0508075A (pt) 2004-03-31 2007-07-17 Bpsi Holdings Inc revestimentos entéricos para substratos de ingestão oral
RS52233B (en) 2004-05-07 2012-10-31 Nycomed Gmbh THE PHARMACEUTICAL DOSAGE FORM CONTAINING GRANULES AND ITS PRODUCTION PROCEDURE
GB0417481D0 (en) 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
KR101398747B1 (ko) * 2004-08-19 2014-05-26 디에스엠 아이피 어셋츠 비.브이. 지용성 물질의 신규한 조성물
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
EP1789090A2 (en) 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US20080113031A1 (en) 2004-09-27 2008-05-15 Joey Moodley Minicapsule Formulations
EP1868567A4 (en) 2005-03-29 2010-09-29 Mcneil Ppc Inc COMPOSITIONS WITH HYDROPHILIC DRUGS IN A HYDROPHOBIC MEDIUM
JP2008535921A (ja) 2005-04-12 2008-09-04 エラン・ファルマ・インターナショナル・リミテッド シクロスポリンを含むナノ粒子および放出調節された組成物
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
JP2009502841A (ja) 2005-07-26 2009-01-29 グラクソ グループ リミテッド 脂質をベースにした製剤の腸溶性ポリマー中へのカプセル化
EP1909771A1 (en) 2005-08-02 2008-04-16 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
JP5398268B2 (ja) 2006-02-09 2014-01-29 アルバ セラピューティクス コーポレーション タイトジャンクション・エフェクター用製剤
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20080124279A1 (en) 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
SG10201508397VA (en) 2007-04-06 2015-11-27 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
JP2010527285A (ja) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
CN101028281B (zh) * 2007-04-29 2010-05-26 于学敏 纳米胶体果胶铋及其颗粒剂药物
US20100239665A1 (en) 2007-05-01 2010-09-23 Ivan Coulter Pharmaceutical nimodipine compositions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2009002533A1 (en) 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
EP2483287B1 (en) 2007-10-12 2016-03-16 Luigi Panza Analogues of glycolipids useful as immunoadjuvants
CN101167704A (zh) * 2007-11-26 2008-04-30 沈阳药科大学 一种诺西肽掩味微囊及其制备方法
NO2105129T3 (pt) 2008-03-24 2018-06-16
CA2729948C (en) 2008-07-08 2021-11-23 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
IE20090793A1 (en) 2008-10-13 2010-06-23 Sigmoid Pharma Ltd A delivery system
EP3300723A1 (en) * 2009-05-18 2018-04-04 Sigmoid Pharma Limited Composition comprising oil drops
JP5911799B2 (ja) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations

Also Published As

Publication number Publication date
GB2483815B (en) 2013-12-25
BRPI1012196B1 (pt) 2021-11-30
PL2471518T3 (pl) 2018-01-31
US20210338768A1 (en) 2021-11-04
US9278070B2 (en) 2016-03-08
CN102470106B (zh) 2015-09-23
EP3300723A1 (en) 2018-04-04
CN102470106A (zh) 2012-05-23
SI2432455T1 (sl) 2015-04-30
EP2432455B1 (en) 2014-11-12
EP2471518A2 (en) 2012-07-04
GB201121682D0 (en) 2012-01-25
US20240115657A1 (en) 2024-04-11
DK2471518T3 (en) 2017-12-04
WO2010133609A2 (en) 2010-11-25
EP2471518A3 (en) 2012-12-26
CN105213318A (zh) 2016-01-06
SG176145A1 (en) 2011-12-29
JP2012527425A (ja) 2012-11-08
US20120141531A1 (en) 2012-06-07
JP5640079B2 (ja) 2014-12-10
CA2762179A1 (en) 2010-11-25
US20160143989A1 (en) 2016-05-26
GB2483815A (en) 2012-03-21
DK2432455T3 (en) 2015-02-16
ES2649112T3 (es) 2018-01-10
WO2010133609A3 (en) 2011-12-01
HRP20150110T1 (hr) 2015-05-08
US20180264076A1 (en) 2018-09-20
ES2530049T3 (es) 2015-02-26
EP2471518B1 (en) 2017-08-23
EP2432455A2 (en) 2012-03-28
US9999651B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
BRPI1012196A2 (pt) composição compreendendo gotas de óleo
FR2944289B1 (fr) Composition huileuse volatile
BR112012005242A2 (pt) composição de óleo anticorrosivo
SMT201600307B (it) Composizione liposomiale
FR2942627B1 (fr) Composition de graisse
BRPI1013588A2 (pt) composição
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
BRPI0921327A2 (pt) Combinação de herbicida-protetor
DK2634231T3 (da) Sammensætninger
UY33161A (es) Composiciones plaguicidas
BRPI1015474A2 (pt) composição
BRPI1013222A2 (pt) composições de mirceno polimérico
FR2949786B1 (fr) Composition de graisse.
BRPI1010842A2 (pt) composição de óleo de laminação de metal
BRPI1010690A2 (pt) composições
DE112009005504A5 (de) Schmiermittelzusammensetzung
BRPI0919037A2 (pt) composições lubrificantes
BR112012002908A2 (pt) óleo de base
BRPI0908558A2 (pt) composição lubrificante
BR112012033194A2 (pt) composição de fluído funcional
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
BRPI1010198A2 (pt) composição de poliamida modificada
BRPI1005318A2 (pt) composição
BRPI0922728A2 (pt) combinação de herbicida-antídoto
BRPI0918012A2 (pt) composicoes liquidas de nisina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: SUBLIMITY THERAPEUTICS LIMITED (IE)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.